Oxidative stress and innate immunity impair the visual cycle
氧化应激和先天免疫会损害视觉周期
基本信息
- 批准号:10117256
- 负责人:
- 金额:$ 53.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-01 至 2022-02-28
- 项目状态:已结题
- 来源:
- 关键词:11 cis RetinalAcuteAddressAffectAge related macular degenerationAntioxidantsAreaBindingBlindnessCD46 AntigenCellsChronicComplementComplement ActivationDataDiseaseElderlyEpitopesFunctional disorderGene ExpressionGenesGeneticImpairmentInflammationInflammatoryInjectionsInjuryLigandsLinkLiteratureMalondialdehydeMediatingMicronutrientsMusMutationNatural ImmunityOxidative StressPathway interactionsRecyclingResearchRetinaRiskRodentRoleSignal TransductionStructure of retinal pigment epitheliumSystemTestingVisionVisualVisual PathwaysVisual impairmentWorkaging populationbevacizumabcytokinedesigneffective therapygene functioninduced pluripotent stem cellinnovationneovascularnotch proteinnovelpreventretinal damagesight restorationtargeted treatmenttranscription factorvisual controlvisual cycle
项目摘要
Project Summary
Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly. At present, no
therapy will restore vision with any form of AMD. To address this shortcoming, this proposal will focus on
mechanisms that could restore vision. The recycling of 11-cis-retinal (11-cRAL) by the visual cycle is an RPE
function that is essential for vision. While oxidative stress and complement are integral factors in AMD
pathophysiology, their impact on the visual cycle is undefined. The objective of this proposal is to define how
oxidative stress and innate immunity impair the visual cycle to decrease vision in AMD. The hypothesis to be
tested is that oxidative stress and impaired complement regulators Cfh and CD46 decrease the visual cycle
network. The proposed specific aims are: 1. Determine the extent that oxidative stress i) impairs Cfh to induce
inflammation which decreases visual cycle gene expression, and ii) induces Ptx3, and by regulating Cfh
abundance, prevents visual cycle decline. This aim will test the extent that decreased Cfh generates
inflammation from increased complement or MDA mediated cytokine expression to activate Stat3, which
decreases visual cycle gene expression, function, and vision, and the impact of Ptx3 on Cfh abundance to
regulate Cfh mediated inflammation. 2. Determine the extent that chronic oxidative stress impairs the visual
cycle through Notch signaling. Oxidative stress activates Notch signaling, which can induce the transcription
factor Sox9 to control the expression of a network of 6 visual cycle genes. While acute Notch signaling
increases Sox9, chronic Notch signaling decreases Sox9. This aim will explore the extent that chronic oxidative
stress activates Notch signaling, and how Notch influences visual cycle function through Sox9. 3. Determine
the extent that CD46 regulates Notch signaling and Sox9 mediated visual cycle gene function. Besides its
complement regulatory action, CD46 binds Jag1 to impede Notch signaling. Thus, decreased CD46 makes
Jag1 available to activate Notch signaling as an alternative, non-complement function. This aim will explore the
extent that decreased CD46 influences Notch signaling and visual cycle function through Jag1. Since CD46 is
not expressed in somatic rodent cells, we will use iPS RPE cells with mutations in key CD46 domains to
address this aim. These contributions are significant because if successful, novel pathways will be identified as
targets to treat vision loss in AMD. The research is innovative since we will investigate understudied areas
including mechanisms of vision loss from the synergistic impact of oxidative stress and innate immunity, the
role of Stat3, Notch, and Sox9, and unconventional, non-complement functions of complement regulators on
the visual cycle using unique, state-of-the-art genetic mice with fresh, but decisive factors that have not been
previously tested. Targeted therapy that neutralizes pathways that degrade visual cycle gene expression,
function, and vision from oxidative stress and overactive innate immunity is expected to result from this work.
项目摘要
视网膜相关性黄斑变性(AMD)是老年人失明的主要原因。目前没有
治疗将恢复任何形式的AMD的视力。为了弥补这一缺陷,本提案将侧重于
可以恢复视力的机制。11-cRAL通过视觉循环的再循环是RPE
这对视力至关重要。氧化应激和补体是AMD发病的重要因素
病理生理学,它们对视觉周期的影响是不确定的。本提案的目的是确定如何
氧化应激和先天免疫损害了AMD的视觉周期,从而降低了视力。假设是
氧化应激和受损的补体调节因子Cfh和CD 46降低了视觉周期
网络建议的具体目标是:1。确定氧化应激i)损害Cfh诱导的程度
炎症降低视觉周期基因表达,和ii)诱导Ptx 3,并通过调节Cfh
丰富,防止视觉周期下降。这一目标将测试Cfh减少产生的程度
炎症来自补体或MDA介导的细胞因子表达增加以激活Stat 3,
降低视觉周期基因表达、功能和视力,Ptx 3对Cfh丰度的影响,
调节Cfh介导的炎症。2.确定慢性氧化应激损害视觉的程度
通过Notch信号循环。氧化应激激活Notch信号,其可以诱导转录
因子Sox 9来控制6个视觉周期基因的网络表达。当急性Notch信号传导
增加Sox 9,慢性Notch信号降低Sox 9。这一目标将探讨慢性氧化性
压力激活Notch信号传导,以及Notch如何通过Sox 9影响视觉周期功能。3.确定
CD 46调节Notch信号传导和Sox 9介导的视觉周期基因功能的程度。除了其
在补体调节作用中,CD 46结合Jag 1以阻碍Notch信号传导。因此,CD 46的减少使
Jag 1可激活Notch信号传导作为替代的非互补功能。这一目标将探讨
CD 46的减少通过Jag 1影响Notch信号通路和视觉周期功能。因为CD 46是
在啮齿动物体细胞中不表达,我们将使用在关键CD 46结构域中具有突变的iPS RPE细胞,
解决这个目标。这些贡献是重要的,因为如果成功,新的途径将被确定为
治疗AMD视力丧失的目标。这项研究是创新的,因为我们将调查未充分研究的领域
包括氧化应激和先天免疫的协同作用导致视力丧失的机制,
Stat 3、Notch和Sox 9的作用,以及补体调节因子的非常规、非补体功能,
视觉周期使用独特的,最先进的基因小鼠,具有新鲜的,但决定性的因素,
以前测试过。靶向治疗,中和降解视觉周期基因表达的途径,
功能和视觉的氧化应激和过度活跃的先天免疫,预计将导致这项工作。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Retinal Anatomy and Electrode Array Position in Retinitis Pigmentosa Patients After Argus II Implantation: An International Study.
- DOI:10.1016/j.ajo.2018.06.012
- 发表时间:2018-09
- 期刊:
- 影响因子:4.2
- 作者:Gregori NZ;Callaway NF;Hoeppner C;Yuan A;Rachitskaya A;Feuer W;Ameri H;Arevalo JF;Augustin AJ;Birch DG;Dagnelie G;Grisanti S;Davis JL;Hahn P;Handa JT;Ho AC;Huang SS;Humayun MS;Iezzi R Jr;Jayasundera KT;Kokame GT;Lam BL;Lim JI;Mandava N;Montezuma SR;Olmos de Koo L;Szurman P;Vajzovic L;Wiedemann P;Weiland J;Yan J;Zacks DN
- 通讯作者:Zacks DN
Cigarette Smoke Triggers Loss of Corneal Endothelial Cells and Disruption of Descemet's Membrane Proteins in Mice.
- DOI:10.1167/iovs.62.3.3
- 发表时间:2021-03-01
- 期刊:
- 影响因子:4.4
- 作者:Ali M;Khan SY;Jang Y;Na CH;Talbot CC Jr;Gottsch JD;Handa JT;Riazuddin SA
- 通讯作者:Riazuddin SA
Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis.
- DOI:10.1177/2474126420975303
- 发表时间:2021-07
- 期刊:
- 影响因子:0
- 作者:Witkin AJ;Hahn P;Murray TG;Arevalo JF;Blinder KJ;Choudhry N;Emerson GG;Goldberg RA;Kim SJ;Pearlman J;Schneider EW;Tabandeh H;Wong RW
- 通讯作者:Wong RW
The impact of lipids, lipid oxidation, and inflammation on AMD, and the potential role of miRNAs on lipid metabolism in the RPE.
- DOI:10.1016/j.exer.2018.09.023
- 发表时间:2019-04
- 期刊:
- 影响因子:3.4
- 作者:Jun S;Datta S;Wang L;Pegany R;Cano M;Handa JT
- 通讯作者:Handa JT
A Role for βA3/A1-Crystallin in Type 2 EMT of RPE Cells Occurring in Dry Age-Related Macular Degeneration.
- DOI:10.1167/iovs.18-24132
- 发表时间:2018-03-20
- 期刊:
- 影响因子:4.4
- 作者:Ghosh S;Shang P;Terasaki H;Stepicheva N;Hose S;Yazdankhah M;Weiss J;Sakamoto T;Bhutto IA;Xia S;Zigler JS Jr;Kannan R;Qian J;Handa JT;Sinha D
- 通讯作者:Sinha D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James T Handa其他文献
James T Handa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James T Handa', 18)}}的其他基金
The role of epigenetics in RPE heterogeneity with early AMD
表观遗传学在早期 AMD RPE 异质性中的作用
- 批准号:
10630096 - 财政年份:2022
- 资助金额:
$ 53.7万 - 项目类别:
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy
针对 AMD 病理学中的溶酶体/RPE 异质性作为一种新疗法
- 批准号:
10636943 - 财政年份:2021
- 资助金额:
$ 53.7万 - 项目类别:
Targeting lysosome/RPE heterogeneity in AMD pathobiology as a novel therapy
针对 AMD 病理学中的溶酶体/RPE 异质性作为一种新疗法
- 批准号:
10407452 - 财政年份:2021
- 资助金额:
$ 53.7万 - 项目类别:
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD
治疗性抑制干性 AMD 中 Fas 介导的视网膜细胞死亡和炎症
- 批准号:
10523617 - 财政年份:2020
- 资助金额:
$ 53.7万 - 项目类别:
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD
治疗性抑制干性 AMD 中 Fas 介导的视网膜细胞死亡和炎症
- 批准号:
10457555 - 财政年份:2020
- 资助金额:
$ 53.7万 - 项目类别:
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD
治疗性抑制干性 AMD 中 Fas 介导的视网膜细胞死亡和炎症
- 批准号:
10093659 - 财政年份:2020
- 资助金额:
$ 53.7万 - 项目类别:
Oxidative stress and innate immunity impair the visual cycle
氧化应激和先天免疫会损害视觉周期
- 批准号:
9260322 - 财政年份:2017
- 资助金额:
$ 53.7万 - 项目类别:
Nrf2 signaling and oxidative stress in Age-related macular degeneration
年龄相关性黄斑变性中的 Nrf2 信号传导和氧化应激
- 批准号:
8212110 - 财政年份:2010
- 资助金额:
$ 53.7万 - 项目类别:
Nrf2 signaling and oxidative stress in Age-related macular degeneration
年龄相关性黄斑变性中的 Nrf2 信号传导和氧化应激
- 批准号:
8420508 - 财政年份:2010
- 资助金额:
$ 53.7万 - 项目类别:
Nrf2 signaling and oxidative stress in age-related macular degeneration
年龄相关性黄斑变性中的 Nrf2 信号传导和氧化应激
- 批准号:
8792217 - 财政年份:2010
- 资助金额:
$ 53.7万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 53.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 53.7万 - 项目类别:
Operating Grants














{{item.name}}会员




